Orphan Drugs of Personalized Medicine in Bulgaria and Their Cost-Effectiveness

Zhaklin Stoykova-Valcheva ()
Additional contact information
Zhaklin Stoykova-Valcheva: Medical University-Varna - Varna, Varna, Bulgaria

Izvestia Journal of the Union of Scientists - Varna. Economic Sciences Series, 2020, vol. 9, issue 3, 52-62

Abstract: The orphan drugs development is related to the progress of personalized medicine. The relationship between them is based on a treatment tailored to personalized patient needs. Personalized medicine is defined as “providing the right patient with the right drug, at the right dose and at the right time”, while the orphan drug is defined as “intended for the treatment, prevention or diagnosis of a rare disease or condition, which is one that affects less than 200,000 persons in the United States” and no more than 10,000 people for the European Union. The main goal of the article is to study the approved orphan drugs in Bulgaria, determining how many of them are reimbursed by the NHIF and are cost-effective.

Keywords: Orphan drug; Personalized medicine; Cost-effectiveness (search for similar items in EconPapers)
JEL-codes: A00 (search for similar items in EconPapers)
Date: 2020
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://su-varna.org/journal/IJUSV-ESS/2020.9.3/52-62.pdf (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:vra:journl:v:9:y:2020:i:3:p:52-62

DOI: 10.36997/IJUSV-ESS/2020.9.3.52

Access Statistics for this article

More articles in Izvestia Journal of the Union of Scientists - Varna. Economic Sciences Series from Union of Scientists - Varna, Economic Sciences Section Contact information at EDIRC.
Bibliographic data for series maintained by Pavel Petrov ().